Lazertinib alone vs lazertinib plus Avastin for EGFR+ lung cancer in smokers
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests if adding bevacizumab (Avastin) to lazertinib works better than lazertinib alone for advanced non-small cell lung cancer with an EGFR mutation. It is for people who have smoked at least 100 cigarettes in their lifetime.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced non-small cell lung cancer (stage IIIB or IV) with an EGFR mutation (exon 19 deletion or L858R).
- You have smoked at least 100 cigarettes in your life (even if you quit).
- You can get around and care for yourself (ECOG score 0 or 1).
- Your blood counts, liver, and kidney functions are adequate as tested.
- You have not had previous chemotherapy or targeted therapy for advanced lung cancer (except certain past treatments finished 6 months ago).
- You are not pregnant, can avoid pregnancy for 6 months after treatment, and do not have uncontrolled high blood pressure, heart disease, or bleeding problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether taking lazertinib before surgery can shrink or control EGFR-mutant lung adenocarcinoma that can be fully removed by an operation. It uses a special liquid biopsy from fluid in the lungs to confirm the EGFR mutation and guide treatment.
This trial tests a combination of two targeted drugs, lazertinib and tepotinib, for people with advanced EGFR-mutant non-small cell lung cancer whose tumors show MET overactivity (high MET levels or MET gene copies) and have grown despite prior treatment with lazertinib. It aims to see if adding tepotinib can overcome that resistance.
This trial compares a combination of anti-angiogenics (bevacizumab) plus chemotherapy (paclitaxel and carboplatin) against Avastin-based treatment in people with advanced non-small cell lung cancer. It aims to find out whether the study treatment is safer and works better for shrinking tumors and improving outcomes.
This study tests whether adding a second drug (bevacizumab) to a first-line EGFR-targeted pill (limertinib) helps people with a specific type of lung cancer (non-squamous NSCLC) live longer and control their cancer better. You must have an EGFR mutation and a high PD-L1 score to join.
This study tests two combinations of drugs to see which works better for people with a specific type of lung cancer that has a change in the EGFR gene. The treatments may help shrink tumors or slow their growth.
This trial tests a new targeted therapy (DZD9008) combined with a drug that blocks blood vessel growth (bevacizumab) for people with a specific type of advanced lung cancer (EGFR mutation). The goal is to see if this combination works better than current treatments.
Hear when a new Lazertinib trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.